THTX vs. CRVS, TRVI, CMPS, AQST, GOSS, CADL, ATYR, IMMP, OLMA, and KRRO
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), COMPASS Pathways (CMPS), Aquestive Therapeutics (AQST), Gossamer Bio (GOSS), Candel Therapeutics (CADL), Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry.
Theratechnologies vs.
Corvus Pharmaceuticals (NASDAQ:CRVS) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.
Corvus Pharmaceuticals received 261 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 61.91% of users gave Corvus Pharmaceuticals an outperform vote while only 53.57% of users gave Theratechnologies an outperform vote.
Theratechnologies has higher revenue and earnings than Corvus Pharmaceuticals. Theratechnologies is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Corvus Pharmaceuticals has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.
In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 1 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Theratechnologies' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.
Corvus Pharmaceuticals currently has a consensus target price of $12.38, suggesting a potential upside of 195.35%. Given Corvus Pharmaceuticals' higher probable upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than Theratechnologies.
Corvus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Corvus Pharmaceuticals beats Theratechnologies on 9 of the 16 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:THTX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free THTX Stock Alerts